CTNM
Contineum Therapeutics Inc-A
NASDAQ · Pharmaceuticals
$15.00
+0.52 (+3.59%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 273.32M | 248.64M | 220.16M |
| Net Income | 33.71M | 25.85M | 22.01M |
| EPS | — | — | — |
| Profit Margin | 12.3% | 10.4% | 10.0% |
| Rev Growth | -0.8% | +22.0% | +2.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 170.90M | 168.09M | 146.24M |
| Total Equity | 266.33M | 244.64M | 253.88M |
| D/E Ratio | 0.64 | 0.69 | 0.58 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 45.63M | 48.42M | 37.59M |
| Free Cash Flow | 26.06M | 26.05M | 25.67M |